Cargando…

LAG-3 and 4-1BB identify dysfunctional antigen-specific T cells in the tumor microenvironment and combinatorial LAG-3/4-1BB targeting gives synergistic tumor control

Detalles Bibliográficos
Autores principales:	Williams, Jason B, Horton, Brendan, Zheng, Yan, Gajewski, Thomas F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649320/ http://dx.doi.org/10.1186/2051-1426-3-S2-P328

Ejemplares similares

The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8(+) T cells in the tumor microenvironment
por: Williams, Jason B., et al.
Publicado: (2017)

Agonistic 4-1bb antibodies in combination with inhibitory antibodies against CTLA-4, PD-L1 or LAG-3 ACT on CD8+ T cells in the tumor microenvironment and synergize to promote regression of established tumors
por: Horton, Brendan, et al.
Publicado: (2014)

Agonist anti-4-1BB plus neutralizing anti-CTLA-4 or -PD-L1 synergize to promote tumor regression by rescuing dying dysfunctional CD8+ T cells within the tumor microenvironment
por: Horton, Brendan, et al.
Publicado: (2015)

Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies
por: Mikkelsen, Kasper, et al.
Publicado: (2019)

LAG-3 expression in tumor microenvironment of triple-negative breast cancer
por: TAHTACI, Gözde, et al.
Publicado: (2022)

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
por: Bartkowiak, Todd, et al.
Publicado: (2015)

Targeting 4-1BB for tumor immunotherapy from bench to bedside
por: Wang, Ya-Tao, et al.
Publicado: (2022)

The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
por: Long, Long, et al.
Publicado: (2018)

LAG-3 expression in the inflammatory microenvironment of glioma
por: Mair, Maximilian J., et al.
Publicado: (2021)

A NOVEL MSLN×4-1BB BISPECIFIC ANTIBODY FOR SOLID TUMOR
por: Cheng, Liansheng, et al.
Publicado: (2023)

T cell activation and anti-tumor efficacy of anti-LAG-3 antibodies is independent of LAG-3 – MHCII blocking capacity
por: Cemerski, Saso, et al.
Publicado: (2015)

LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures
por: Gestermann, Nicolas, et al.
Publicado: (2020)

In silico and phylogenetic analyses of partial BbRAP-1, BbCP2, BbSBP-4 and BbβTUB gene sequences of Babesia bovis isolates from cattle in South Africa
por: Mtshali, Phillip Senzo, et al.
Publicado: (2017)

4-1BB (CD137) in anticancer chimeras
por: Melero, Ignacio, et al.
Publicado: (2020)

SPS collider mode timing requirements for BB4 and BB5 experimental areas
por: Beetham, G
Publicado: (1980)

An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation
por: Muik, Alexander, et al.
Publicado: (2022)

PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
por: Zahm, Christopher D., et al.
Publicado: (2021)

The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer
por: Kozłowski, Mateusz, et al.
Publicado: (2022)

LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2020)

Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more
por: Turnis, Meghan E., et al.
Publicado: (2012)

4-1BB agonism: adding the accelerator to cancer immunotherapy
por: Chester, Cariad, et al.
Publicado: (2016)

4-1BB: A promising target for cancer immunotherapy
por: Kim, Alyssa Min Jung, et al.
Publicado: (2022)

Search for the radion decay into a Higgs boson pair with $\gamma\gamma +bb, \tau\tau+bb$ and $bb+bb$ final states
por: Gennai, Simone
Publicado: (2004)

Galectin-3 Decreases 4-1BBL Bioactivity by Crosslinking Soluble and Membrane Expressed 4-1BB
por: Nielsen, Morten Aagaard, et al.
Publicado: (2022)

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
por: Jiang, Haiping, et al.
Publicado: (2021)

Understanding LAG-3 Signaling
por: Chocarro, Luisa, et al.
Publicado: (2021)

PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
por: Okazaki, Taku, et al.
Publicado: (2011)

Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma
por: Cheung, Chun Chau Lawrence, et al.
Publicado: (2023)

bbH
por: Asawatangtrakuldee, Chayanit
Publicado: (2022)

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
por: Lichtenegger, Felix S., et al.
Publicado: (2018)

4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors
por: Long, Adrienne H., et al.
Publicado: (2015)

Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma
por: Wang, Yitian, et al.
Publicado: (2019)

Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors
por: Feucht, J., et al.
Publicado: (2020)

CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy
por: Michot, Jean-Marie, et al.
Publicado: (2021)

LAG3’s Enigmatic Mechanism of Action
por: Graydon, Colin G., et al.
Publicado: (2021)

Overcoming the LAG3 phase problem
por: Petersen, Jan, et al.
Publicado: (2022)

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
por: Compte, Marta, et al.
Publicado: (2018)

Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens
por: Zhao, Yuan, et al.
Publicado: (2012)

4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2(nd) Generation Chimeric Antigen Receptor-Modified T Cells
por: Dai, Qiang, et al.
Publicado: (2020)

Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade
por: Warmuth, Stefan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4mg16e4uc6sh5ct31gv13vs9le